Clinical Outcomes of Comparison Between Type III Coronary Artery Perforation (CAP) and non-CAP Acute Coronary Syndrome Patients During 3-Year Follow-up.
Bekir S YildizRamazan GunduzSu OzgurAhmet Y CizgiciIbrahim H OzdemirPublished in: Angiology (2023)
Coronary artery perforation (CAP) is a potentially fatal complication of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). This study aimed to investigate in-hospital, 1-year, and 3-year clinical outcomes of type III CAP during PCI in patients with ACS. The study retrospectively evaluated 118 patients with CAP and 43,226 case-control patients. Clinical, angiographic, and procedural characteristics, management, and outcomes were analyzed retrospectively at 1-year and 3-year follow-ups. The mean age of the patients was 66.5 ± 11.9 years (61.8% males). There was no significant difference in hospital mortality between the type III CAP and non-CAP groups. The all-cause mortality was 33.3% in the CAP group vs 1.8% in the non-CAP group at 1 year, and 28.3% in CAP group vs 6.9% in non-CAP group at 3 years ( p = .001 for both comparisons). The procedural, clinical, and 1 and 3-year outcomes of type III CAP showed a relatively high risk of myocardial infarction, coronary artery bypass graft, cerebrovascular event, stent thrombosis, and major bleeding at the 1 and 3-year follow-ups. In addition, non-CAP ACS patients had better survival (log-rank: p < .001, 34.29 months 95% Confidence Interval [33.58-35.00]) than type III CAP ACS patients (29.53 months 95% Confidence Interval [27.28-31.78]) at the 3-year follow-up visit.
Keyphrases
- acute coronary syndrome
- type iii
- percutaneous coronary intervention
- end stage renal disease
- coronary artery
- ejection fraction
- chronic kidney disease
- healthcare
- antiplatelet therapy
- prognostic factors
- peritoneal dialysis
- heart failure
- acute myocardial infarction
- coronary artery disease
- emergency department
- st segment elevation myocardial infarction
- adipose tissue
- pulmonary artery
- patient reported outcomes
- pulmonary arterial hypertension
- insulin resistance
- adverse drug
- drug induced